Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium
ABSTRACT The use of a liquid biopsy to assess molecular residual disease (MRD) of solid tumors holds significant promise for improving outcomes for patients with cancer. Liquid biopsies are a minimally invasive approach for the identification of circulating tumor biomarkers through a simple blood sa...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | Clinical and Translational Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/cts.70185 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849389071992881152 |
|---|---|
| author | Andrew G. Hadd Angela Silvestro Brittany Avin McKelvey Jonathan Baden Christina Bormann Chung Ben Brown Fernando Cruz‐Guilloty James Godsey Gregory Jones Cheng‐Ho Jimmy Lin Dorys Lopez Ramos Daniel Norton Melanie R. Palomares Carol Pena Thereasa Rich Angel Rodriguez Mark Stewart Diana Merino Vega Lauren C. Leiman |
| author_facet | Andrew G. Hadd Angela Silvestro Brittany Avin McKelvey Jonathan Baden Christina Bormann Chung Ben Brown Fernando Cruz‐Guilloty James Godsey Gregory Jones Cheng‐Ho Jimmy Lin Dorys Lopez Ramos Daniel Norton Melanie R. Palomares Carol Pena Thereasa Rich Angel Rodriguez Mark Stewart Diana Merino Vega Lauren C. Leiman |
| author_sort | Andrew G. Hadd |
| collection | DOAJ |
| description | ABSTRACT The use of a liquid biopsy to assess molecular residual disease (MRD) of solid tumors holds significant promise for improving outcomes for patients with cancer. Liquid biopsies are a minimally invasive approach for the identification of circulating tumor biomarkers through a simple blood sample. Assays capable of detecting MRD through analysis of circulating tumor DNA (ctDNA) are rapidly evolving for clinical study applications and therapeutic interventions. To address these opportunities, BLOODPAC—a multi‐disciplinary consortium representing stakeholders from public, industry, academia, and regulatory agencies—formulated a lexicon that provides a shared framework and clear definitions using liquid biopsies for solid tumor MRD with an emphasis on ctDNA detection. The terms in the lexicon are categorized under general MRD, ctDNA testing methodologies, reporting results, and acquisition timepoints, including examples of current and potential clinical use cases for MRD tests. The overall goal is to provide a unified language and approaches to solid tumor MRD to advance applications of these technologies, allow data aggregation to strengthen future evidence, and facilitate regulatory approvals, leading to the use of liquid biopsy as an early endpoint in clinical trials. We believe that a common set of terminology and methods for solid tumor MRD can improve understanding and appropriate use of testing, accelerate clinical development, and improve outcomes for cancer patients. |
| format | Article |
| id | doaj-art-b30347af16814c6ea25edaa71db542ac |
| institution | Kabale University |
| issn | 1752-8054 1752-8062 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj-art-b30347af16814c6ea25edaa71db542ac2025-08-20T03:42:04ZengWileyClinical and Translational Science1752-80541752-80622025-03-01183n/an/a10.1111/cts.70185Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC ConsortiumAndrew G. Hadd0Angela Silvestro1Brittany Avin McKelvey2Jonathan Baden3Christina Bormann Chung4Ben Brown5Fernando Cruz‐Guilloty6James Godsey7Gregory Jones8Cheng‐Ho Jimmy Lin9Dorys Lopez Ramos10Daniel Norton11Melanie R. Palomares12Carol Pena13Thereasa Rich14Angel Rodriguez15Mark Stewart16Diana Merino Vega17Lauren C. Leiman18Natera Austin Texas USAGSK Waltham Massachusetts USAFriends of Cancer Research Washington DC USABristol Myers Squibb Lawrence Township New Jersey USAGRAIL, Inc. Menlo Park California USAAdela Bio Foster City California USAJohnson & Johnson New Brunswick New Jersey USAQuest Diagnostics Secaucus New Jersey USANeoGenomics Fort Myers Florida USAFreenome San Francisco California USABLOODPAC Chicago Illinois USAPersonalis Fremont California USAExact Sciences Madison Wisconsin USAMerck & co., Inc. Rahway New Jersey USAGuardant Health Palo Alto California USANatera Austin Texas USAFriends of Cancer Research Washington DC USAAstraZeneca Gaithersburg Maryland USABLOODPAC Chicago Illinois USAABSTRACT The use of a liquid biopsy to assess molecular residual disease (MRD) of solid tumors holds significant promise for improving outcomes for patients with cancer. Liquid biopsies are a minimally invasive approach for the identification of circulating tumor biomarkers through a simple blood sample. Assays capable of detecting MRD through analysis of circulating tumor DNA (ctDNA) are rapidly evolving for clinical study applications and therapeutic interventions. To address these opportunities, BLOODPAC—a multi‐disciplinary consortium representing stakeholders from public, industry, academia, and regulatory agencies—formulated a lexicon that provides a shared framework and clear definitions using liquid biopsies for solid tumor MRD with an emphasis on ctDNA detection. The terms in the lexicon are categorized under general MRD, ctDNA testing methodologies, reporting results, and acquisition timepoints, including examples of current and potential clinical use cases for MRD tests. The overall goal is to provide a unified language and approaches to solid tumor MRD to advance applications of these technologies, allow data aggregation to strengthen future evidence, and facilitate regulatory approvals, leading to the use of liquid biopsy as an early endpoint in clinical trials. We believe that a common set of terminology and methods for solid tumor MRD can improve understanding and appropriate use of testing, accelerate clinical development, and improve outcomes for cancer patients.https://doi.org/10.1111/cts.70185ctDNAliquid biopsyMRD |
| spellingShingle | Andrew G. Hadd Angela Silvestro Brittany Avin McKelvey Jonathan Baden Christina Bormann Chung Ben Brown Fernando Cruz‐Guilloty James Godsey Gregory Jones Cheng‐Ho Jimmy Lin Dorys Lopez Ramos Daniel Norton Melanie R. Palomares Carol Pena Thereasa Rich Angel Rodriguez Mark Stewart Diana Merino Vega Lauren C. Leiman Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium Clinical and Translational Science ctDNA liquid biopsy MRD |
| title | Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium |
| title_full | Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium |
| title_fullStr | Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium |
| title_full_unstemmed | Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium |
| title_short | Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium |
| title_sort | establishing a common lexicon for circulating tumor dna analysis and molecular residual disease insights from the bloodpac consortium |
| topic | ctDNA liquid biopsy MRD |
| url | https://doi.org/10.1111/cts.70185 |
| work_keys_str_mv | AT andrewghadd establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT angelasilvestro establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT brittanyavinmckelvey establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT jonathanbaden establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT christinabormannchung establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT benbrown establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT fernandocruzguilloty establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT jamesgodsey establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT gregoryjones establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT chenghojimmylin establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT doryslopezramos establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT danielnorton establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT melanierpalomares establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT carolpena establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT thereasarich establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT angelrodriguez establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT markstewart establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT dianamerinovega establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium AT laurencleiman establishingacommonlexiconforcirculatingtumordnaanalysisandmolecularresidualdiseaseinsightsfromthebloodpacconsortium |